

Dear Author,

Here are the proofs of your article.

- You can submit your corrections **online**, via **e-mail** or by **fax**.
- For **online** submission please insert your corrections in the online correction form. Always indicate the line number to which the correction refers.
- You can also insert your corrections in the proof PDF and **email** the annotated PDF.
- For fax submission, please ensure that your corrections are clearly legible. Use a fine black pen and write the correction in the margin, not too close to the edge of the page.
- Remember to note the **journal title**, **article number**, and **your name** when sending your response via e-mail or fax.
- **Check** the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown.
- **Check** the questions that may have arisen during copy editing and insert your answers/corrections.
- **Check** that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the *Edited manuscript*.
- The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct.
- Please **do not** make changes that involve only matters of style. We have generally introduced forms that follow the journal's style. Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof.
- If we do not receive your corrections **within 48 hours**, we will send you a reminder.
- Your article will be published **Online First** approximately one week after receipt of your corrected proofs. This is the **official first publication** citable with the DOI. **Further changes are, therefore, not possible.**
- The **printed version** will follow in a forthcoming issue.

#### Please note

After online publication, subscribers (personal/institutional) to this journal will have access to the complete article via the DOI using the URL: [http://dx.doi.org/\[DOI\]](http://dx.doi.org/[DOI]).

If you would like to know when your article has been published online, take advantage of our free alert service. For registration and further information go to: <http://www.link.springer.com>.

Due to the electronic nature of the procedure, the manuscript and the original figures will only be returned to you on special request. When you return your corrections, please inform us if you would like to have these documents returned.

# Metadata of the article that will be visualized in OnlineFirst

**Please note: Images will appear in color online but will be printed in black and white.**

ArticleTitle	Effects of Aib residues insertion on the structural–functional properties of the frog skin-derived peptide Esculentin-1a(1–21)-NH <sub>2</sub>
--------------	--

Article Sub-Title	
-------------------	--

Article CopyRight	Springer-Verlag Wien (This will be the copyright line in the final PDF)
-------------------	--

Journal Name	Amino Acids
--------------	-------------

Corresponding Author	Family Name	<b>Mangoni</b>
	Particle	
	Given Name	<b>Maria Luisa</b>
	Suffix	
	Division	Department of Biochemical Sciences, Istituto Pasteur-Fondazione Cenci Bolognetti
	Organization	Sapienza University of Rome
	Address	Via degli Apuli, 9, 00185, Rome, Italy
	Phone	+39 06 49917693
	Fax	
	Email	marialuisa.mangoni@uniroma1.it
	URL	
	ORCID	

Author	Family Name	<b>Biondi</b>
	Particle	
	Given Name	<b>Barbara</b>
	Suffix	
	Division	Padova Unit, CNR
	Organization	Institute of Biomolecular Chemistry
	Address	Via Marzolo 1, 35131, Padova, Italy
	Phone	
	Fax	
	Email	
	URL	
	ORCID	

Author	Family Name	<b>Casciaro</b>
	Particle	
	Given Name	<b>Bruno</b>
	Suffix	
	Division	Department of Biochemical Sciences, Istituto Pasteur-Fondazione Cenci Bolognetti
	Organization	Sapienza University of Rome
	Address	Via degli Apuli, 9, 00185, Rome, Italy
	Phone	
	Fax	
	Email	
	URL	
	ORCID	

Fax  
Email  
URL  
ORCID

---

Author	Family Name	<b>Grazia</b>
	Particle	<b>Di</b>
	Given Name	<b>Antonio</b>
	Suffix	
	Division	Department of Biochemical Sciences, Istituto Pasteur-Fondazione Cenci Bolognetti
	Organization	Sapienza University of Rome
	Address	Via degli Apuli, 9, 00185, Rome, Italy
	Phone	
	Fax	
	Email	
	URL	
	ORCID	

---

Author	Family Name	<b>Cappiello</b>
	Particle	
	Given Name	<b>Floriana</b>
	Suffix	
	Division	Department of Biochemical Sciences, Istituto Pasteur-Fondazione Cenci Bolognetti
	Organization	Sapienza University of Rome
	Address	Via degli Apuli, 9, 00185, Rome, Italy
	Phone	
	Fax	
	Email	
	URL	
	ORCID	

---

Author	Family Name	<b>Luca</b>
	Particle	
	Given Name	<b>Vincenzo</b>
	Suffix	
	Division	Department of Biochemical Sciences, Istituto Pasteur-Fondazione Cenci Bolognetti
	Organization	Sapienza University of Rome
	Address	Via degli Apuli, 9, 00185, Rome, Italy
	Phone	
	Fax	
	Email	
	URL	
	ORCID	

---

Author	Family Name	<b>Crisma</b>
	Particle	
	Given Name	<b>Marco</b>

Suffix  
 Division Padova Unit, CNR  
 Organization Institute of Biomolecular Chemistry  
 Address Via Marzolo 1, 35131, Padova, Italy  
 Phone  
 Fax  
 Email  
 URL  
 ORCID

Schedule	Received	2 August 2016
	Revised	
	Accepted	28 September 2016
Abstract	<p>Antimicrobial peptides (AMPs) play a key role in the defence mechanism of living organisms against microbial pathogens, displaying both bactericidal and immunomodulatory properties. They are considered as a promising alternative to the conventional antibiotics towards which bacteria are becoming highly resistant. Recently, a derivative of the frog skin AMP Esculentin-1a, Esculentin-1a(1–21)NH<sub>2</sub> [Esc(1–21)], showed a strong and fast membranolytic activity against Gram-negative bacteria but with a lower efficacy against Gram-positive ones. Here, with the aim to increase the <math>\alpha</math>-helicity of Esc(1–21) and the expected potency against Gram-positive bacteria, we designed an analog bearing three <math>\alpha</math>-aminoisobutyric acid (Aib) residues at positions 1, 10, and 18 of its primary structure. We demonstrated that the incorporation of Aib residues: (1) promoted the <math>\alpha</math>-helix conformation of Esc(1–21), as confirmed by circular dichroism and two-dimensional nuclear magnetic resonance spectroscopies; (2) was sufficient to make this analog more active than the parent peptide against several Gram-positive bacterial strains without affecting its activity against Gram-negative bacteria; and (3) resulted to be devoid of toxic effect toward epithelial cells at the active antimicrobial concentrations. These results suggest that replacement of L-amino acids with Aib residues has beneficial effects on the structure and properties of the membrane-active peptide Esc(1–21), making it a better candidate for the design and development of selective drugs against Gram-positive bacteria.</p>	
Keywords (separated by '-')	Antimicrobial peptides - $\alpha$ -Aminoisobutyric acid - Gram-positive bacteria - NMR	
Footnote Information	Handling Editor: M. S. Palma.	

# 2 Effects of Aib residues insertion on the structural–functional 3 properties of the frog skin-derived peptide Esculentin-1a(1–21)-NH<sub>2</sub>

4 Barbara Biondi<sup>1</sup> · Bruno Casciaro<sup>2</sup> · Antonio Di Grazia<sup>2</sup> · Floriana Cappiello<sup>2</sup> ·  
5 Vincenzo Luca<sup>2</sup> · Marco Crisma<sup>1</sup> · Maria Luisa Mangoni<sup>2</sup>

6 Received: 2 August 2016 / Accepted: 28 September 2016  
7 © Springer-Verlag Wien 2016

**AQ1 Abstract** Antimicrobial peptides (AMPs) play a key role in the defence mechanism of living organisms against microbial pathogens, displaying both bactericidal and immunomodulatory properties. They are considered as a promising alternative to the conventional antibiotics towards which bacteria are becoming highly resistant. Recently, a derivative of the frog skin AMP Esculentin-1a, Esculentin-1a(1–21)NH<sub>2</sub> [Esc(1–21)], showed a strong and fast membranolytic activity against Gram-negative bacteria but with a lower efficacy against Gram-positive ones. Here, with the aim to increase the  $\alpha$ -helicity of Esc(1–21) and the expected potency against Gram-positive bacteria, we designed an analog bearing three  $\alpha$ -aminoisobutyric acid (Aib) residues at positions 1, 10, and 18 of its primary structure. We demonstrated that the incorporation of Aib residues: (1) promoted the  $\alpha$ -helix conformation of Esc(1–21), as confirmed by circular dichroism and two-dimensional nuclear magnetic resonance spectroscopies; (2) was sufficient to make this analog more active than the parent peptide against several Gram-positive bacterial strains without affecting its activity against Gram-negative bacteria; and (3) resulted to be devoid of toxic effect toward epithelial cells at the active antimicrobial concentrations. These results suggest that replacement of L-amino acids with Aib residues has beneficial effects on the structure and properties of the membrane-active peptide Esc(1–21),

making it a better candidate for the design and development of selective drugs against Gram-positive bacteria.

**Keywords** Antimicrobial peptides ·  $\alpha$ -Aminoisobutyric acid · Gram-positive bacteria · NMR

## Abbreviations

CD	Circular dichroism	34
DIEA	<i>N,N</i> -Diisopropylethylamine	35
DMEM	Dulbecco's modified Eagle's medium	36
FBS	Heat-inactivated fetal bovine serum	37
HATU	1-[Bis(dimethylamino)methylene]-1 <i>H</i> -1,2,3-triazolo[4,5- <i>b</i> ]pyridinium 3-oxide hexafluorophosphate	38
HBTU	<i>N,N,N',N'</i> -Tetramethyl- <i>O</i> -(1 <i>H</i> -benzotriazol-1-yl)uronium hexafluorophosphate	39
HOBt	1-Hydroxybenzotriazole	40
MBHA	4-Methylbenzhydrylamine	41
MH	Mueller–Hinton	42
MTT	3(4,5-Dimethylthiazol-2yl)2,5-diphenyltetrazolium bromide	43
NMR	Nuclear magnetic resonance	44
SDS	Sodium dodecylsulfate	45
TFA	Trifluoroacetic acid	46
TFE	Trifluoroethanol	47

## Introduction

Ribosomally made antimicrobial peptides (AMPs) are produced by all species of life throughout the evolutionary scale as principal components of their innate defence system against invading microorganisms (Gonzalez-Navajas et al. 2014; Mangoni and Shai 2011; Mookherjee and Hancock 2007; Nicolas and Mor 1995). Furthermore, they are endowed with immunomodulatory properties (Choi et al.

A1 Handling Editor: M. S. Palma.

A2 ✉ Maria Luisa Mangoni  
A3 marialuisa.mangoni@uniroma1.it

A4 <sup>1</sup> Padova Unit, CNR, Institute of Biomolecular Chemistry, Via  
A5 Marzolo 1, 35131 Padova, Italy

A6 <sup>2</sup> Department of Biochemical Sciences, Istituto  
A7 Pasteur-Fondazione Cenci Bolognietti, Sapienza University  
A8 of Rome, Via degli Apuli, 9, 00185 Rome, ITALY



2012; Hemshekhar et al. 2016) which have led to the more appropriate designation of “host-defence peptides” (Hancock et al. 2016; Mansour et al. 2014). More specifically, amphibian skin dermal glands, controlled by sympathetic nerves, are among the richest sources of biologically active peptides with pharmacological and antimicrobial activities (Chen et al. 2003; Conlon 2011; Erspamer 1971; Haslam et al. 2014; König et al. 2014; Mangoni et al. 2015). They are stored within granules and released on the skin surface by a holocrine mechanism, upon alarm or physical injury (Mangoni et al. 2001, 2007). Each frog species produces its own unique set of AMPs encompassing families of 2–100 closely related members (Mangoni 2006). Esculentins-1 are a class of frog skin AMPs, characterized by a 46 amino acids primary structure and a broad range of antimicrobial activity (Gamberi et al. 2007; Mangoni et al. 2003; Ponti et al. 2003; Simmaco et al. 1994). Studies on their mode of action pointed out the bacterial membrane as the major target. Esculentins-1 possess features common to most linear AMPs, i.e., an overall positive charge at neutral pH and a considerable proportion of hydrophobic residues (Simmaco et al. 1994). These properties are instrumental in allowing an electrostatic interaction between the cationic AMP and the negatively charged components of the microbial cell surface followed by the peptide’s folding into an amphiphilic structure, with a resulting perturbation of the cell membrane permeability and hence cell death (Ganz and Lehrer 1998; Haney et al. 2010; Lohner and Blondelle 2005; Shai 2002). Importantly, in contrast with the conventional antibiotics that interfere with biological events by processes involving specific recognition of chiral targets (Bai et al. 2011; Levy 2002; Savjani et al. 2009), the mechanism of action underlying the killing activity of AMPs is generally based on the physical disruption of the target cell membrane, thus limiting the induction of microbial resistance (Hancock and Rozek 2002; Lohner 2016). Indeed, to become resistant to AMPs, microbes should drastically change the composition of their membrane, an event that could not be achieved without causing a significant harm to the microorganism itself (Mangoni 2006; Mangoni and Shai 2011). It is worth recalling that the membrane of mammalian cells is much richer in zwitterionic phospholipids as compared with that of microbial cells and this difference is one of the major reasons accounting for the preferential activity of AMPs towards bacterial and fungal cells (Epand and Vogel 1999).

The previous studies reported that the N-terminal derivative of esculentin-1a, Esc-1a(1–21)NH<sub>2</sub>, [Esc(1–21)] corresponding to its first 20 amino acids followed by an amidated Gly residue (H-Gly-Ile-Phe-Ser-Lys-Leu-Ala-Gly-Lys-Lys-Ile-Lys-Asn-Leu-Leu-Ile-Ser-Gly-Leu-Lys-Gly-NH<sub>2</sub>) adopts an alpha-helical conformation in a membrane-mimicking environment and retains the antimicrobial

activity of the full-length peptide esculentin-1a (Gamberi et al. 2007; Ghosh et al. 2016). More recently, Esc(1–21) was shown to display a fast membranolytic activity against both planktonic and biofilm forms of the multi-drug resistant (MDR) opportunistic Gram-negative bacterium *Pseudomonas aeruginosa* (Breidenstein et al. 2011; Drenkard and Ausubel 2002; Kolar et al. 2015; Luca et al. 2013; Uccelletti et al. 2010). This bacterium has the ability to colonize both inert surfaces (such as those of medical devices, e.g., contact lenses) and biological tissues, forming biofilm communities (Hoiby et al. 2011; Parsek and Tolker-Nielsen 2008; Rybtke et al. 2015) which can easily lead to acute and chronic infections, including otitis, pneumonia, and keratitis (Abbouda et al. 2014; Bodey et al. 1983). However, a lower efficacy has been shown by Esc(1–21) against Gram-positive bacteria (Kolar et al. 2015).

In this connection, with the aim of enlarging the spectrum of activity of Esc(1–21) especially against Gram-positive bacteria as well as its biostability to proteases, we explored the effects of the incorporation of  $\alpha$ -aminoisobutyric acid (Aib) residues into the peptide sequence. When inserted into the primary structure of peptides, this strongly helicogenic, non-coded, C $^{\alpha}$ -tetrasubstituted  $\alpha$ -amino acid is expected to increase the  $\alpha$ -helical content of the molecule (Karle and Balaram 1990; Toniolo et al. 2001) and potentially confers it a higher resistance against enzymatic degradation (De Zotti et al. 2009, 2012; Yamaguchi et al. 2003). Furthermore, it was previously demonstrated that a stabilized  $\alpha$ -helical structure is an essential requirement to enhance the microbicidal activity of a peptide against Gram-positive bacteria and fungi (Giangaspero et al. 2001). In this work, we report on the synthesis of an analog of Esc(1–21), bearing three Aib residues at sequence position 1, 10, and 18 [(Aib<sup>1,10,18</sup>)-Esc(1–21)]; its structural characterization in different environments, by circular dichroism (CD) and two-dimensional nuclear magnetic resonance spectroscopies (2D-NMR) techniques, as well as its biological activity, and compared these results with those of the parent peptide Esc(1–21).

## Materials and methods

### Materials

Fmoc-amino acids were supplied from Novabiochem (Merck Biosciences, La Jolla, CA, USA), and all other amino-acid derivatives and reagents for peptide synthesis were purchased from Sigma-Aldrich (St. Louis, MO, USA). 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) was purchased from GLS (Shanghai, China). Trypsin-EDTA was purchased from Invitrogen (Life-Technologies Europe,



Monza, Italy); 3(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) was from Sigma-Aldrich (St. Luis, MO). Dulbecco's modified Eagle's medium (DMEM), heat-inactivated fetal bovine serum (FBS), glutamine, gentamycin, and penicillin/streptomycin were from Euroclone (Milan, Italy). Esc(1–21) was purchased from Selleck Chemicals (Houston, TX, USA) and purified according to (Di Grazia et al. 2015a, b).

### Synthesis of [Aib<sup>1,10,18</sup>]-Esc (1–21)

Assembly of the peptide on the Advanced ChemTech (Louisville, KY, USA) 348 Ω peptide synthesizer was performed on a 0.06-mmol scale by the FastMoc methodology [HBTU, HOBt, DIEA, single acylation protocol, 45 min coupling time, *N,N*-dimethylformamide (DMF) as the solvent], starting with Rink Amide MBHA resin (Iris Biotech, Marktredwitz, Germany) (95 mg, loading 0.65 mmol g<sup>-1</sup>). The deprotection of the Fmoc group was performed with a 20 % piperidine solution in DMF in two steps of 5 and 15 min, respectively. The coupling steps involving Aib residues, carried out in presence of HATU, were repeated twice. Boc and *t*Bu side-chain protections were used for Lys and Ser residues, respectively. Cleavage of the peptide from the resin, concomitantly with side-chain deprotections, was achieved by treatment with trifluoroacetic acid (TFA)/triisopropylsilane (TIS)/water (95:2.5:2.5 v/v). The crude peptide was purified by reverse-phase flash chromatography using a Biotage Isolera Prime (Uppsala, Sweden) purification system. The chromatographically homogeneous, final peptide was characterized by electrospray ionization mass spectrometry (ESI-MS) and NMR.

### Microorganisms

The microorganisms used for the antimicrobial assays were the reference Gram-negative bacteria *Acinetobacter baumannii* ATCC 19606, *Escherichia coli* D21, *E. coli* ATCC 25922; *Pseudomonas aeruginosa* ATCC 27853, *Yersinia pseudotuberculosis* YPIII, and the Gram-positive bacteria *Bacillus megaterium* Bm11, *Staphylococcus epidermidis* ATCC 12228, as well as the clinical isolates *Staphylococcus aureus* 6938; *Staphylococcus capitis* 1; *Staphylococcus epidermidis* 21; and *Staphylococcus hominis* 1. In addition, two *Candida* strains were employed: the reference *Candida albicans* ATCC 10231 and *C. guillier mondii* from the frog natural flora (Mangoni et al. 2001).

### Antimicrobial assay

Susceptibility testing was performed by adapting the microbroth dilution method outlined by the Clinical and Laboratory Standards Institute, using sterile 96-well plates

(Falcon NJ, USA). The bacterial growth was aseptically measured by absorbance at 590 nm with a spectrophotometer (UV-1700 Pharma Spec Shimadzu, Tokyo, Japan). Aliquots (50 μl) of bacteria in mid-log phase at a concentration of  $2 \times 10^6$  colony-forming units (CFU)/mL in culture medium (Mueller–Hinton, MH) were added to 50 μl of MH broth containing the peptide in serial twofold dilutions ranging from 64 to 0.25 μM. Inhibition of microbial growth was visually observed, after 18-h incubation at 37 °C. Antibacterial activity was expressed as the minimal inhibitory concentration (MIC), the concentration of peptide causing 100 % inhibition of microbial growth. The same procedure was followed with yeasts in Winge medium (Valenti et al. 1985) using a final cell concentration of  $3.5 \times 10^4$  CFU/ml and an incubation time of 18 h at 30 °C.

### Cell cultures

The human type II alveolar epithelial cell line A549 cells (from the American Type Culture Collection) and the human immortalized keratinocytes (HaCaT) cell line were employed. Cells were cultured in DMEM containing 10 % heat-inactivated fetal bovine serum (FBS) and supplemented with L-glutamine (2 mM or 4 mM for A549 or HaCaT cells, respectively) and antibiotics (0.1 mg/ml of penicillin and streptomycin for A549 cells; 0.05 mg/ml of gentamicin for HaCaT cells) at 37 °C and 5 % CO<sub>2</sub> in 25-cm<sup>2</sup> flasks.

### Peptides' effect on cell viability

The effect of both peptides on the viability of mammalian cells was determined by the inhibition of MTT reduction to insoluble formazan, by mitochondrial reductases. Cells suspended in the corresponding culture medium supplemented with glutamine and 2 % FBS without antibiotics were plated in triplicate wells of a microtiter plate, at  $4 \times 10^4$  cells/well. After overnight incubation at 37 °C in a 5 % CO<sub>2</sub> atmosphere, the medium was replaced with 100-μl fresh serum-free medium containing the peptides at different concentrations. The plate was incubated for 2 h or 24 h at 37 °C in a 5 % CO<sub>2</sub> atmosphere (Paiva et al. 2012). Then, the culture medium was removed and replaced with Hank's buffer (136-mM NaCl; 4.2-mM Na<sub>2</sub>HPO<sub>4</sub>; 4.4-mM KH<sub>2</sub>PO<sub>4</sub>; 5.4-mM KCl; 4.1-mM NaHCO<sub>3</sub>, pH 7.2, supplemented with 20-mM D-glucose) containing 0.5 mg/ml MTT. After 4 h incubation, the formazan crystals were dissolved by adding 100 μl of acidified isopropanol and viability was determined by absorbance measurements at 570 nm using a microplate reader (Infinite M200; Tecan, Salzburg, Austria). Cell viability was calculated with respect to the control (cells not treated with peptide). The percentage of viable cells was calculated according to the formula:



$$\frac{(\text{Absorbance sample} - \text{Absorbance blank})}{(\text{Absorbance control} - \text{Absorbance blank})} \times 100,$$

where the blank is given by samples without cells and not treated with the peptide.

## Circular dichroism spectroscopy

The CD spectra were measured on a Jasco (Hachioji City, Japan) model J-715 spectropolarimeter equipped with a Haake thermostat (Thermo Fisher Scientific, Waltham, MA, USA). Milli-Q grade water, spectrograde methanol, and TFE (Acros Organic, Geel, Belgium) were used as solvents. Peptide concentrations were determined by UV absorption at 254 nm. For each spectrum, a total of eight scans were averaged. Baselines were corrected by subtracting the solvent contribution. Fused quartz cell of 0.1-mm path length (Hellma, Mühlheim, Germany) was used. For the experiments carried out in mixed solvents, the proper ratio of the individual solutions at the same concentration was mixed. The values are expressed in terms of  $[\theta]_T$ , the total molar ellipticity ( $\text{deg} \times \text{cm}^2 \times \text{dmol}^{-1}$ ).

## Nuclear magnetic resonance spectrometry

Samples for NMR spectrometry were dissolved in TFE- $\text{d}_2$  solution (peptide concentrations: about 1 and 1.5 mM, respectively, for Esc(1–21) and its Aib<sup>1,10,18</sup> analog. The spectra were recorded at 298 K. All NMR experiments were performed on a Bruker Avance DMX-600 spectrometer using the TOPSPIN 1.3 software package. Presaturation of the  $\text{H}_2\text{O}$  signal was obtained using a WATERGATE gradient program. All homonuclear spectra were acquired by collecting 512 experiments, each one consisting of 64–80 scans and 2 K data points. The spin systems of the protein amino-acid residues were identified using the standard DQF-COSY (Rance et al. 1983) and CLEAN-TOCSY (Bax and Davis 1985; Griesinger et al. 1988) spectra. In the latter case, the spin-lock pulse sequence was 70-ms long. NOESY experiments were used for sequence-specific assignment (Wüthrich 1986), the mixing time used was 150 ms to avoid spin-diffusion problems.

## Statistical analysis

Data were collected from three independent experiments. Quantitative data are expressed as the mean  $\pm$  SEM. Statistical analysis was performed using the two-way analysis of variance (ANOVA), with the PRISM software (GraphPad, San Diego, CA, USA). Differences were considered to be statistically significant for  $p < 0.05$ . The levels of statistical significance are indicated in the legend to figures.

## Results and discussion


### Synthesis

We synthesized an analog of Esc(1–21) in which we inserted three Aib residues at positions 1, 10, and 18. The choice of the sequence positions of Esc(1–21) to be replaced by Aib was based on the following considerations: (1) the placement of a non-coded Aib residue at position 1 might prevent proteolytic degradation by aminopeptidases, whereas an amidated peptide C-terminus is known to confer protection against carboxypeptidases (Rink et al. 2010; Veber and Freidinger 1985), thus suggesting that the presence of a C-terminal Aib would not be necessary. Concerning the protection by endopeptidases, the introduction of a few additional Aib replacements, possibly quite evenly distributed along the primary structure, is expected to be (at least to some extent) beneficial. (2) The helix-promoting capabilities of Aib are more effective when this residue is placed *internal* to the peptide sequence, where it can display its influence on both the preceding and the following residues in the primary sequence. (3) A helical wheel plot of the primary structure of Esc(1–21), where residues are arranged according to an ideal  $\alpha$ -helical folding, is shown in Fig. 1a. In this putative fully  $\alpha$ -helical conformation, two faces can be identified, one possessing a more pronounced hydrophobic character and the other a more hydrophilic one. However, strongly hydrophobic residues, such as Ile2, Leu6, and Ile16, are located on the same face occupied by the five charged Lys residues. (4) It is worth recalling that in naturally occurring Aib-rich amphipathic helical peptides of fungal origin known as peptaibiotics (Toniolo and Brückner 2009), the Aib residues are, in general, located within the hydrophobic face but also at its boundary with the hydrophilic one. The most striking example of this latter disposition is provided by the lipopeptide trichogin (Toniolo et al. 1994). All together, these observations suggested us to place three Aib residues in the Esc(1–21) sequence; two of them at positions 1 and 18 (both as a replacement for Gly), and one in substitution for Lys<sup>10</sup>, i.e., at the boundary between the hydrophilic and hydrophobic faces (Fig. 1b). As a result of this latter replacement, the overall net charge decreases by one unit if compared with that of the parent peptide, and the overall hydrophilic/hydrophobic profile becomes slightly modified. We principally preferred to give priority to the increase of the helical propensity and proteolytic stability of the central part of the sequence expected as a result of the Lys<sup>10</sup>  $\rightarrow$  Aib<sup>10</sup> substitution, even if accompanied by the potentially unfavorable effects outlined above. For the solid-phase peptide synthesis of [Aib<sup>1,10,18</sup>]-Esc (1–21), we exploited a well-established protocol concerning the use of a strong activating





**Fig. 1** Helical wheel plots of the primary structure of Esc(1–21) (a) and its [Aib<sup>1,10,18</sup>] analog (b)



agent, HATU, in the coupling reactions involving Aib residues (De Zotti et al. 2012). The synthesis was performed on a Rink amide MBHA resin using an Fmoc N<sup>α</sup> protection protocol as described in “Materials and methods”. The cleavage of the peptide from the resin was achieved using a mixture of TFA/TIS/H<sub>2</sub>O. The crude peptide was obtained in 80 % yield with a purity of 85 %, as evidenced by RP-HPLC. Reverse-phase flash chromatography allowed the isolation of the peptide with 97 % purity.

H-Aib<sup>1</sup>-Ile-Phe-Ser-Lys-Leu-Ala-Gly-Lys-Aib<sup>10</sup>-Ile-Lys-Asn-Leu-Leu-Ile-Ser-Aib<sup>18</sup>-Leu-Lys-Gly-NH<sub>2</sub>

	MW (calcd for C <sub>104</sub> H <sub>185</sub> N <sub>27</sub> O <sub>24</sub> )	MW (experi- mental)	t <sub>r</sub> (min)	Purity
[Aib <sup>1,10,18</sup> ]- Esc(1–21)	2196.41	2196.40	9.38 <sup>a</sup>	97 %

<sup>a</sup> Elution conditions: Jupiter C18 column, 300 Å, 5 μm; 30–60 % B in 20 min (A: 9:1 water/acetonitrile, 0.05 % TFA; B: 9:1 acetonitrile/water, 0.05 % TFA)

### Antimicrobial activity

The activity of [Aib<sup>1,10,18</sup>]-Esc(1–21) against different microorganisms, including Gram-negative, Gram-positive bacteria, and yeasts, was tested by the microdilution broth assay to determine the MIC. In comparison with the parent peptide, the incorporation of Aib residues sharply increases the activity of the peptide against Gram-positive bacteria, as shown by its lower MICs in Table 1. More specifically, the MIC of the analog carrying Aib residues is eight-fold lower against *S. epidermidis* strains or 16-fold lower against *S. capitis* 1. Furthermore, the antibacterial activity of [Aib<sup>1,10,18</sup>]-Esc(1–21) becomes even stronger against *S. aureus*, with a 32-fold lower MIC than that of Esc(1–21). Interestingly, in line with what previously found for the de novo designed P19 peptide (Giangaspero et al. 2001),

**Table 1** Antimicrobial activity of Esc(1–21) and [Aib<sup>1,10,18</sup>]-Esc(1–21)

Microorganisms	MIC (μM)	
	Esc(1–21)	[Aib <sup>1,10,18</sup> ]-Esc(1–21)
Gram-negative bacteria		
<i>Acinetobacter baumannii</i> ATCC 19606	2	2
<i>Escherichia coli</i> ATCC 25922	4	2
<i>Escherichia coli</i> D21	2	2
<i>Pseudomonas aeruginosa</i> ATCC 27853	4	4
<i>Yersinia pseudotuberculosis</i> YPIII	1	1
Gram-positive bacteria		
<i>Bacillus megaterium</i> Bm11	2	0.5
<i>Staphylococcus aureus</i> 6938	64	2
<i>Staphylococcus capitis</i> 1	64	4
<i>Staphylococcus epidermidis</i> ATCC 12228	16	2
<i>Staphylococcus epidermidis</i> 21	16	2
<i>Staphylococcus hominis</i> 1	1	1
Yeasts		
<i>Candida albicans</i> ATCC 10231	4	2
<i>Candida guillier mondii</i>	1	1

<sup>a</sup> Values are those obtained from at least three of four independent experiments

the presence of Aib residues within the peptide sequence does not significantly affect the activity of the peptide against Gram-negative bacteria, as indicated by the same MIC values to those of the parent peptide (Table 1), with the exception of *E. coli* ATCC 25922 towards which the analog results to be only twice as powerful as Esc(1–21). In addition, the anti-yeast activity is not significantly influenced by the presence of Aib residues, and the MIC against

*Candida* strains is equal or twofold lower than that of Esc(1–21). It is very well known that the cell selectivity of AMPs is governed by several biophysical and biochemical factors, including not only the peptide's cationicity, amphipathicity, hydrophobicity, chain length, helicity, and oligomeric state, but also the properties of the target cell surface (Glukhov et al. 2005; Matsuzaki 2009). In the last 15 years, several studies reported that an amphipathic structure is a primary requirement for AMPs to be able to kill Gram-positive bacteria and fungi, while Gram-negative bacteria remain susceptible to both non-helical and scrambled peptides (Dathe et al. 1996, 1997; Giangaspero et al. 2001). However, it is not easy to provide an unequivocal explanation for the difference in the activity profile of Esc(1–21) and its Aib-containing analog against the three classes of microorganisms. The different lipid composition existing between the membrane of Gram-positive and Gram-negative bacteria or fungi certainly plays a crucial role in determining the feasibility of the peptide's insertion into the hydrophobic core of the phospholipid bilayer, which results in membrane destabilization/perturbation and microbial death (Epand et al. 2007; Epand and Vogel 1999). In addition, differences in the cell wall architecture of the target microorganism would contribute to variations in the peptides' antimicrobial efficacy. Indeed, before reaching the target, cytoplasmic membrane AMPs need to interact with lipopolysaccharides of the outer membrane that surrounds the cell wall in Gram-negative bacteria (Bhunia et al. 2009, 2010; Domadia et al. 2010). Differently, a thicker peptidoglycan or a glucan-rich layer is present in the cell wall of Gram-positive bacteria or fungi, respectively (Free 2013; Schaffer and Messner 2005). Presumably, according to the previous studies (Giangaspero et al. 2001), more stringent structural requirements of a peptide may favor its translocation through the peptidoglycan barrier of Gram-positive bacteria into the cytoplasmic membrane. This observation may at least in part justify the lower MIC values found for the more helical [Aib<sup>1,10,18</sup>]-Esc(1–21) compared with the parent Esc(1–21) against these bacterial strains.

### Peptides' effect on viability of mammalian cell lines

The effect of Aib introduction within the primary structure of Esc(1–21) on the viability of eukaryotic cells was studied by the MTT assay on different types of mammalian epithelial cell lines: the human alveolar lung epithelial A549 cells and the human keratinocyte HaCaT cells. As reported in Fig. 2a, viability of A549 cells after exposure to [Aib<sup>1,10,18</sup>]-Esc(1–21) at concentrations 2–4  $\mu$ M is not significantly reduced and there is no significant difference between the two peptides.

Similarly, when [Aib<sup>1,10,18</sup>]-Esc(1–21) is analyzed against HaCaT cells (Fig. 2b), any marked reduction in the

number of metabolically active cells is obtained within the peptide concentrations of 2–4  $\mu$ M compared with the harmless parent peptide. These findings suggest that [Aib<sup>1,10,18</sup>]-Esc(1–21) is not toxic to mammalian cells when used at its growth inhibitory concentrations against Gram-positive bacteria (Table 1). Note, however, that when the Aib-containing analog is tested at higher concentrations, i.e., 16, 32, and 64  $\mu$ M, against A549 cells, cell viability decreases to ~60, 20, and 5 %, respectively (Fig. 2a) or even further when the peptide is assayed against keratinocytes (Fig. 2b). As reported in Fig. 2c and d, the cytotoxicity of [Aib<sup>1,10,18</sup>]-Esc(1–21) is only slightly increased after a long-term peptide treatment (24 h), indicating that an irreversible damage has been caused to the cells.

Note that the higher cytotoxicity of the more helical Aib-containing Esc(1–21) is in agreement with the previous findings showing that the ease of  $\alpha$ -helix formation and stability are important factors for the mammalian membrane perturbation and cell lysis (Gazit et al. 1994; Pouny et al. 1992; Shai and Oren 1996; Strahilevitz et al. 1994).


### Circular dichroism

Far-UV CD spectra of Esc(1–21) and its (Aib<sup>1,10,18</sup>) analog were acquired in three different solvents: water, TFE, and 100-mM sodium dodecyl sulfate (SDS) aqueous solution (Fig. 3a, b). In water, both peptides exhibit a random coil structure, while in TFE and micellar SDS aqueous solution, they adopt an overall helical conformation. In both membrane-mimicking environments, each spectrum shows two negative maxima near 205 and 222 nm and one positive maximum at 195 nm, indicative of a right-handed helical conformation for both peptides (Beychock 1967). The ellipticity ratio  $R = [\theta]_{222}/[\theta]_{205}$  calculated in TFE and SDS solution evidenced a predominant  $\alpha$ -helical conformation for both analogs (Mangoni and Shai 2011).

	$R_{\text{SDS}}$	$R_{\text{TFE}}$
Esc(1–21)	0.76	0.76
[Aib <sup>1,10,18</sup> ]-Esc(1–21)	0.92	0.75

The CD results outlined above would seem to suggest that the two compounds are conformationally similar. However, a significant difference emerges from the analysis of the CD spectra collected in water/TFE mixtures of varying composition (Fig. 3c, d). Indeed, for each peptide, the set of spectra is characterized by an isodichroic point at 203 nm, consistent with a two-state transition from the unordered conformation in water to the helical structure in 100 % TFE. The helical content of Esc(1–21) increases sharply with increasing TFE percentage from 20 to 50 % and to a lower extent from 50 to 100 % TFE (Fig. 3c), whereas the Aib-containing analog appears to be much more helical





**Fig. 2** Peptides' effect on the viability of A549 cells (a, c) or HaCaT cells (b, d). Cells were plated in wells of a microtiter plate, at  $4 \times 10^4$  cells/well in culture medium, as described in the Experimental section. After overnight incubation at 37 °C in a 5 % CO<sub>2</sub> atmosphere, the medium was replaced with 100-μl fresh medium supplemented with the peptides at different concentrations. After 2 h (a, b) or 24 h (c, d) of peptide treatment, cell viability was determined by the MTT

reduction to insoluble formazan. Cell viability is expressed as percentage with respect to the control (cells not treated with the peptide). Data points represent the mean of triplicate samples  $\pm$  SEM. The data of the wild-type peptide Esc(1–21) on HaCaT cells were taken from our previous work (Di Grazia et al. 2015a). The levels of statistical significance between the two peptides are: \*\*\* $p < 0.001$ ; \*\*\*\* $p < 0.0001$

than the parent peptide already at 20 % TFE, and its CD spectra vary little at higher TFE percentages (Fig. 3d).

### Nuclear magnetic resonance analysis

The 2D-NMR spectra of Esc(1–21) and its (Aib<sup>1,10,18</sup>) analog were recorded in TFE solution. The proton resonances were fully assigned following the Wüthrich procedure (Wüthrich 1986).

The NOESY spectra in TFE solution of both peptides evidenced the presence of most of NH<sub>*i*</sub>–NH<sub>*i*+1</sub> sequential cross peaks, indicative of the occurrence of helical structure (Fig. 4), thus confirming the information obtained from CD spectra.

The NOESY fingerprint region of Esc(1–21) shows the C<sup>α</sup>H<sub>*i*</sub> → NH<sub>*i*+2</sub> and C<sup>α</sup>H<sub>*i*</sub> → NH<sub>*i*+3</sub> cross peaks, diagnostic of helical conformation (Fig. 4a), even if a C<sup>α</sup>H<sub>*i*</sub> → NH<sub>*i*+4</sub> cross peak, characteristic of α-helical structure could be detected only in the Phe<sup>3</sup>–Ala<sup>7</sup> segment (although the extensive overlapping of the signals might hamper their detection in other portions of the sequence).

The fingerprint region of the NOESY spectrum of the (Aib<sup>1,10,18</sup>) analog results better resolved (Fig. 4b). A


number of connectivities are necessarily missing, because the quaternary Aib residues (at sequence positions 1, 10, and 18) lack the α hydrogen atom. Nevertheless, in addition to the C<sup>α</sup>H<sub>*i*</sub> → NH<sub>*i*+2</sub> and C<sup>α</sup>H<sub>*i*</sub> → NH<sub>*i*+3</sub> cross peaks (the latter in a larger number if compared to the parent peptide), two C<sup>α</sup>H<sub>*i*</sub> → NH<sub>*i*+4</sub> are also evident at the level of the Phe<sup>3</sup>–Ala<sup>7</sup> and Leu<sup>15</sup>–Leu<sup>19</sup> segments.

A comparison of the conformationally relevant signatures extracted from the NOESY spectra of Esc(1–21) and its (Aib<sup>1,10,18</sup>) analog is reported in Fig. 5. Overall, in the C-terminal portion of the (Aib<sup>1,10,18</sup>) analog, the number of connectivities consistent with a helical conformation is more abundant than in the corresponding region of Esc(1–21). Therefore, both peptides are largely helical, but the introduction of Aib residues appears to increase the population and stability of the helix in the otherwise more flexible C-terminal domain of Esc(1–21).

### Conclusions and perspectives

In this work, we demonstrated that the increased alpha-helical content of Esc(1–21), obtained by incorporation of






**Fig. 3** Far-UV CD spectra of: **a** Esc(1–21) and **b** [Aib<sup>1,10,18</sup>]-Esc(1–21) in three different environments: water, TFE, and 100 mM SDS solution; **c** Esc(1–21) and **d** [Aib<sup>1,10,18</sup>]-Esc(1–21) in water, 20 % TFE, 50 % TFE, and 100 % TFE (peptide concentration 1 mM)

three non-proteinogenic Aib residues at positions 1, 10, and 18 (as shown by CD and NMR studies) is sufficient to provoke a dramatic increase in the peptide's activity against Gram-positive bacteria without significantly increasing its

toxicity towards epithelial cells at antimicrobial concentrations. This suggests that the Aib designed analog is a better candidate than the wild-type peptide for the development of a new drug against Gram-positive bacterial infections, such




**Fig. 4** Fingerprint region of the H/H-NOESY spectrum of Esc(1–21) (a) and [Aib<sup>1,10,18</sup>]-Esc(1–21) (b) (600 MHz, 1.1 and 1.4 mM, respectively, in TFE-d<sub>2</sub> solution, 298 K). The C<sup>α</sup>H<sub>i</sub> → NH<sub>i+2</sub> (red), C<sup>α</sup>H<sub>i</sub> → NH<sub>i+3</sub> (green), and C<sup>α</sup>H<sub>i</sub> → NH<sub>i+4</sub> (blue) cross peaks, diagnostic of helical conformation, are highlighted



as those associated with the human skin or the lung (Lee et al. 2015; Soufi and Soufi 2016). Nevertheless, considering the toxicity of this analog at concentrations higher than the MICs, it would also be useful to develop this peptide

for further applications, such as those related to the usage of friendly biocides against Gram-positive bacterial communities on metal surfaces in marine engineering systems, e.g., pipelines of the offshore oil and gas industry, to





**Fig. 5** Summary of the significant interresidue NOESY cross peaks for Esc(1–21) (a) and [Aib<sup>1,10,18</sup>]-Esc(1–21) (b) in TFE-d<sub>2</sub> solution. Peptide concentration 1.1 and 1.4 mM, respectively

prevent substantial corrosion problems and contamination of agricultural lands (Godwin and Akpan 2014; Schwermer et al. 2008).

**Acknowledgments** This work was supported by grants from Sapienza Università di Roma and by FILAS Grant Prot. FILAS-RU-2014-1020. This article does not contain any studies with human participants or animals performed by any of the authors.

## References

- Abbouda A, Abicca I, Alio JL (2014) Infectious keratitis following corneal crosslinking: a systematic review of reported cases: management, visual outcome, and treatment proposed. *Semin Ophthalmol*
- Bai H, Zhou Y, Hou Z, Xue X, Meng J, Luo X (2011) Targeting bacterial RNA polymerase: promises for future antisense antibiotics development. *Infect Disord Drug Targets* 11:175–187
- Bax A, Davis DG (1985) MLEV-17-based two dimensional homonuclear magnetization transfer spectroscopy. *J Magn Reson* 65:355–360
- Beychock S (1967) Circular dichroism of poly- $\alpha$ -amino acids and proteins. In: Fasman GD (ed) *Poly- $\alpha$ -amino acids: protein models for conformational studies*. Dekker, New York, pp 293–337

- Bhunia A, Ramamoorthy A, Bhattacharjya S (2009) Helical hair-pin structure of a potent antimicrobial peptide MSI-594 in lipopolysaccharide micelles by NMR spectroscopy. *Chemistry* 15:2036–2040
- Bhunia A, Domadia PN, Torres J, Hallock KJ, Ramamoorthy A, Bhattacharjya S (2010) NMR structure of pardaxin, a pore-forming antimicrobial peptide, in lipopolysaccharide micelles: mechanism of outer membrane permeabilization. *J Biol Chem* 285:3883–3895
- Bodey GP, Bolivar R, Fainstein V, Jadeja L (1983) Infections caused by *Pseudomonas aeruginosa*. *Rev Infect Dis* 5:279–313
- Breidenstein EB, de la Fuente-Nunez C, Hancock RE (2011) *Pseudomonas aeruginosa*: all roads lead to resistance. *Trends Microbiol* 19:419–426
- Chen T, Farragher S, Bjourson AJ, Orr DF, Rao P, Shaw C (2003) Granular gland transcriptomes in stimulated amphibian skin secretions. *Biochem J* 371:125–130
- Choi KY, Chow LN, Mookherjee N (2012) Cationic host defence peptides: multifaceted role in immune modulation and inflammation. *J Innate Immun* 4:361–370
- Conlon JM (2011) Structural diversity and species distribution of host-defense peptides in frog skin secretions. *Cell Mol Life Sci* 68:2303–2315
- Dathe M, Wiprecht T, Nikolenko H, Handel L, Maloy WL, MacDonald DL, Beyermann M, Bienert M (1997) Hydrophobicity, hydrophobic moment and angle subtended by charged residues modulate antibacterial and haemolytic activity of amphipathic helical peptides. *FEBS Lett* 403:208–212





- Dathe M, Schumann M, Wieprecht T, Winkler A, Beyermann M, Krause E, Matsuzaki K, Murase O, Bienert M (1996) Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. *Biochemistry* 35:12612–12622
- De Zotti M, Biondi B, Formaggio F, Toniolo C, Stella L, Park Y, Hahm KS (2009) Trichogin GA IV: an antibacterial and protease-resistant peptide. *J Pept Sci* 15:615–619
- De Zotti M, Biondi B, Park Y, Hahm KS, Crisma M, Toniolo C, Formaggio F (2012) Antimicrobial lipopeptaibol trichogin GA IV: role of the three Aib residues on conformation and bioactivity. *Amino Acids* 43:1761–1777
- Di Grazia A, Cappiello F, Imanishi A, Mastrofrancesco A, Picardo M, Paus R, Mangoni ML (2015a) The frog skin-derived antimicrobial peptide esculentin-1a(1–21)NH<sub>2</sub> promotes the migration of human HaCaT keratinocytes in an EGF receptor-dependent manner: a novel promoter of human skin wound healing? *PLoS One* 10:e0128663
- Di Grazia A, Cappiello F, Cohen H, Casciaro B, Luca V, Pini A, Di YP, Shai Y, Mangoni ML (2015b) D-Amino acids incorporation in the frog skin-derived peptide esculentin-1a(1–21)NH<sub>2</sub> is beneficial for its multiple functions. *Amino Acids* 47:2505–2519
- Domadia PN, Bhunia A, Ramamoorthy A, Bhattacharjya S (2010) Structure, interactions, and antibacterial activities of MSI-594 derived mutant peptide MSI-594F5A in lipopolysaccharide micelles: role of the helical hairpin conformation in outer-membrane permeabilization. *J Am Chem Soc* 132:18417–18428
- Drenkard E, Ausubel FM (2002) *Pseudomonas* biofilm formation and antibiotic resistance are linked to phenotypic variation. *Nature* 416:740–743
- Epand RF, Savage PB, Epand RM (2007) Bacterial lipid composition and the antimicrobial efficacy of cationic steroid compounds (Ceragenins). *Biochim Biophys Acta* 1768:2500–2509
- Epand RM, Vogel HJ (1999) Diversity of antimicrobial peptides and their mechanisms of action. *Biochim Biophys Acta* 1462:11–28
- Ersparmer V (1971) Biogenic amines and active polypeptides of the amphibian skin. *Annu Rev Pharmacol* 11:327–350
- Free SJ (2013) Fungal cell wall organization and biosynthesis. *Adv Genet* 81:33–82
- Gamberi T, Cavalieri D, Magherini F, Mangoni ML, De Filippo C, Borro M, Gentile G, Simmaco M, Modesti A (2007) An integrated analysis of the effects of Esculentin 1–21 on *Saccharomyces cerevisiae*. *Biochim Biophys Acta* 1774:688–700
- Ganz T, Lehrer RI (1998) Antimicrobial peptides of vertebrates. *Curr Opin Immunol* 10:41–44
- Gazit E, Lee WJ, Brey PT, Shai Y (1994) Mode of action of the antibacterial cecropin B2: a spectrofluorometric study. *Biochemistry* 33:10681–10692
- Ghosh A, Bera S, Shai Y, Mangoni ML, Bhunia A (2016) NMR structure and binding of esculentin-1a (1–21)NH<sub>2</sub> and its diastereomer to lipopolysaccharide: correlation with biological functions. *Biochim Biophys Acta* 1858:800–812
- Giangaspero A, Sandri L, Tossi A (2001) Amphipathic alpha helical antimicrobial peptides. *Eur J Biochem* 268:5589–5600
- Glukhov E, Stark M, Burrows LL, Deber CM (2005) Basis for selectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes. *J Biol Chem* 280:33960–33967
- Godwin U, Akpan MGS (2014) Effects of different concentrations of biocides on biofilm microorganisms in oil pipelines in Irri, Delta State, Nigeria. *Int J Biosci* 4:16
- Gonzalez-Navajas JM, Corr MP, Raz E (2014) The immediate protective response to microbial challenge. *Eur J Immunol* 44:2536–2549
- Griesinger COG, Wüthrich K, Ernst RR (1988) Clean TOCSY for proton spin system identification in macromolecules. *J Am Chem Soc* 110:7870–7872
- Hancock RE, Rozek A (2002) Role of membranes in the activities of antimicrobial cationic peptides. *FEMS Microbiol Lett* 206:143–149
- Hancock RE, Haney EF, Gill EE (2016) The immunology of host defence peptides: beyond antimicrobial activity. *Nat Rev Immunol* 16:321–334
- Haney EF, Nathoo S, Vogel HJ, Prenner EJ (2010) Induction of non-lamellar lipid phases by antimicrobial peptides: a potential link to mode of action. *Chem Phys Lipids* 163:82–93
- Haslam IS, Roubos EW, Mangoni ML, Yoshizato K, Vaudry H, Kloepper JE, Pattwell DM, Maderson PF, Paus R (2014) From frog integument to human skin: dermatological perspectives from frog skin biology. *Biol Rev Camb Philos Soc* 89:618–655
- Hemshekhar M, Anaparti V, Mookherjee N (2016) Functions of cationic host defense peptides in immunity. *Pharmaceuticals* 9(3)
- Hoiby N, Ciofu O, Johansen HK, Song ZJ, Moser C, Jensen PO, Molin S, Givskov M, Tolker-Nielsen T, Bjarnsholt T (2011) The clinical impact of bacterial biofilms. *Int J Oral Sci* 3:55–65
- Islas-Rodriguez AE, Marcellini L, Orioni B, Barra D, Stella L, Mangoni ML (2009) Esculentin 1–21: a linear antimicrobial peptide from frog skin with inhibitory effect on bovine mastitis-causing bacteria. *J Pept Sci* 15:607–614
- Karle IL, Balam P (1990) Structural characteristics of alpha-helical peptide molecules containing Aib residues. *Biochemistry* 29:6747–6756
- Kolar SS, Luca V, Baidouri H, Mannino G, McDermott AM, Mangoni ML (2015) Esculentin-1a(1–21)NH<sub>2</sub>: a frog skin-derived peptide for microbial keratitis. *Cell Mol Life Sci* 72:617–627
- Konig E, Bininda-Emonds OR, Shaw C (2014) The diversity and evolution of anuran skin peptides. *Peptides* 63C:96–117
- Lee YR, Hounque C, Hall RG (2015) Treatment of community-acquired pneumonia. *Expert Rev Anti Infect Ther* 13:1109–1121
- Levy SB (2002) The 2000 Garrod lecture. Factors impacting on the problem of antibiotic resistance. *J Antimicrob Chemother* 49:25–30
- Lohner K (2016) Novel antibiotics based upon the multiple mechanisms of membrane perturbation by antimicrobial peptides. *Curr Top Med Chem (in press)*
- Lohner K, Blondelle SE (2005) Molecular mechanisms of membrane perturbation by antimicrobial peptides and the use of biophysical studies in the design of novel peptide antibiotics. *Comb Chem High Throughput Screen* 8:241–256
- Luca V, Stringaro A, Colone M, Pini A, Mangoni ML (2013) Esculentin(1–21), an amphibian skin membrane-active peptide with potent activity on both planktonic and biofilm cells of the bacterial pathogen *Pseudomonas aeruginosa*. *Cell Mol Life Sci* 70:2773–2786
- Mangoni ML (2006) Temporins, anti-infective peptides with expanding properties. *Cell Mol Life Sci* 63:1060–1069
- Mangoni ML, Shai Y (2011) Short native antimicrobial peptides and engineered ultrashort lipopeptides: similarities and differences in cell specificities and modes of action. *Cell Mol Life Sci* 68:2267–2280
- Mangoni ML, Marcellini HG, Simmaco M (2007) Biological characterization and modes of action of temporins and bombinins H, multiple forms of short and mildly cationic anti-microbial peptides from amphibian skin. *J Pept Sci* 13:603–613
- Mangoni ML, Luca V, McDermott AM (2015) Fighting microbial infections: A lesson from amphibian skin-derived esculentin-1 peptides. *Peptides* 71:286–295
- Mangoni ML, Miele R, Renda TG, Barra D, Simmaco M (2001) The synthesis of antimicrobial peptides in the skin of *Rana esculenta* is stimulated by microorganisms. *FASEB J* 15:1431–1432
- Mangoni ML, Fiocco D, Mignogna G, Barra D, Simmaco M (2003) Functional characterisation of the 1-18 fragment of



- 730 esculentin-1b, an antimicrobial peptide from *Rana esculenta*.  
731 Peptides 24:1771–1777
- 732 Manning MC, Woody RW (1991) Theoretical CD studies of polypep-  
733 tide helices: examination of important electronic and geometric  
734 factors. Biopolymers 31:569–586
- 735 Mansour SC, Pena OM, Hancock RE (2014) Host defense peptides:  
736 front-line immunomodulators. Trends Immunol 35:443–450
- 737 Matsuzaki K (2009) Control of cell selectivity of antimicrobial pep-  
738 tides. Biochim Biophys Acta 1788:1687–1692
- 739 Mookherjee N, Hancock RE (2007) Cationic host defence peptides:  
740 innate immune regulatory peptides as a novel approach for treat-  
741 ing infections. Cell Mol Life Sci 64:922–933
- 742 Nicolas P, Mor A (1995) Peptides as weapons against microorganisms  
743 in the chemical defense system of vertebrates. Annu Rev Micro-  
744 biol 49:277–304
- 745 Paiva AD, de Oliveira MD, de Paula SO, Baracat-Pereira MC, Breu-  
746 kink E, Mantovani HC (2012) Toxicity of bovicin HC5 against  
747 mammalian cell lines and the role of cholesterol in bacteriocin  
748 activity. Microbiology 158:2851–2858
- 749 Parsek MR, Tolker-Nielsen T (2008) Pattern formation in *Pseu-*  
750 *domonas aeruginosa* biofilms. Curr Opin Microbiol 11:560–566
- 751 Ponti D, Mangoni ML, Mignogna G, Simmaco M, Barra D (2003)  
752 An amphibian antimicrobial peptide variant expressed in *Nico-*  
753 *tiana tabacum* confers resistance to phytopathogens. Biochem J  
754 370:121–127
- 755 Pouny Y, Rapaport D, Mor A, Nicolas P, Shai Y (1992) Interaction of  
756 antimicrobial dermaseptin and its fluorescently labeled analogues  
757 with phospholipid membranes. Biochemistry 31:12416–12423
- 758 Rance M, Sorensen OW, Bodenhausen G, Wagner G, Ernst RR,  
759 Wuthrich K (1983) Improved spectral resolution in cosy 1H  
760 NMR spectra of proteins via double quantum filtering. Biochem  
761 Biophys Res Commun 117:479–485
- 762 Rink R, Arkema-Meter A, Baudoin I, Post E, Kuipers A, Nelemans  
763 SA, Akanbi MH, Moll GN (2010) To protect peptide phar-  
764 maceuticals against peptidases. J Pharmacol Toxicol Methods  
765 61:210–218
- 766 Rybtke M, Hultqvist LD, Givskov M, Tolker-Nielsen T (2015) *Pseu-*  
767 *domonas aeruginosa* Biofilm Infections: Community Structure,  
768 Antimicrobial Tolerance and Immune Response. J Mol Biol  
769 427:3628–3645
- 770 Savjani JK, Gajjar AK, Savjani KT (2009) Mechanisms of resistance:  
771 useful tool to design antibacterial agents for drug-resistant bac-  
772 teria. Mini Rev Med Chem 9:194–205
- 773 Schaffer C, Messner P (2005) The structure of secondary cell wall  
774 polymers: how Gram-positive bacteria stick their cell walls  
775 together. Microbiology 151:643–651
- Schwermer CU, Lavik G, Abed RM, Dunsmore B, Ferdelman TG, 776  
Stoodley P, Gieseke A, de Beer D (2008) Impact of nitrate on the 777  
structure and function of bacterial biofilm communities in pipe- 778  
lines used for injection of seawater into oil fields. Appl Environ 779  
Microbiol 74:2841–2851 780
- Shai Y (2002) Mode of action of membrane active antimicrobial pep- 781  
tides. Biopolymers 66:236–248 782
- Shai Y, Oren Z (1996) Diastereoisomers of cytolysins, a novel class of 783  
potent antibacterial peptides. J Biol Chem 271:7305–7308 784
- Simmaco M, Mignogna G, Barra D, Bossa F (1994) Antimicrobial 785  
peptides from skin secretions of *Rana esculenta*. Molecular cloning 786  
of cDNAs encoding esculentin and brevinins and isolation of 787  
new active peptides. J Biol Chem 269:11956–11961 788
- Soufi Y, Soufi B (2016) Mass spectrometry-based bacterial proteom- 789  
ics: focus on dermatologic microbial pathogens. Front Microbiol 790  
7:181 791
- Strahilevitz J, Mor A, Nicolas P, Shai Y (1994) Spectrum of anti- 792  
microbial activity and assembly of dermaseptin-b and its 793  
precursor form in phospholipid membranes. Biochemistry 794  
33:10951–10960 795
- Toniolo C, Crisma M, Formaggio F, Peggion C (2001) Control of pep- 796  
tide conformation by the Thorpe-Ingold effect (C alpha-tetrasub- 797  
stitution). Biopolymers 60:396–419 798
- Toniolo C, Peggion C, Crisma M, Formaggio F, Shui X, Eggleston DS 799  
(1994) Structure determination of racemic trichogin A IV using 800  
centrosymmetric crystals. Nat Struct Biol 1:908–914 801
- Toniolo C, Brückner H (2009) Peptaibiotics: fungal peptides contain- 802  
ing  $\alpha$ -dialkyl  $\alpha$ -amino Acids. Wiley-VCH and VHCA, Wein- 803  
heim/Zürich. Chem Biochem 10:2266–2267 804
- Uccelletti D, Zanni E, Marcellini L, Palleschi C, Barra D, Mangoni 805  
ML (2010) Anti-*Pseudomonas* activity of frog skin antimicro- 806  
bial peptides in a *Caenorhabditis elegans* infection model: a 807  
plausible mode of action in vitro and in vivo. Antimicrob Agents 808  
Chemother 54:3853–3860 809
- Valenti P, Visca P, Antonini G, Orsi N (1985) Antifungal activ- 810  
ity of ovotransferrin towards genus *Candida*. Mycopathologia 811  
89:169–175 812
- Veber DF, Freidinger RM (1985) The design of metabolically-stable 813  
peptide analogs. Trends Neurosci 8:392–396 814
- Wüthrich K (1986) NMR of proteins and nucleic acids. Wiley, New 815  
York 816
- Yamaguchi H, Kodama H, Osada S, Kato F, Jelokhani-Niaraki M, 817  
Kondo M (2003) Effect of alpha, alpha-dialkyl amino acids on 818  
the protease resistance of peptides. Biosci Biotechnol Biochem 819  
67:2269–2272 820



## Author Query Form

**Please ensure you fill out your response to the queries raised below and return this form along with your corrections**

Dear Author

During the process of typesetting your article, the following queries have arisen. Please check your typeset proof carefully against the queries listed below and mark the necessary changes either directly on the proof/online grid or in the 'Author's response' area provided below

Query	Details Required	Author's Response
AQ1	Kindly check and confirm the edit made in the title.	
AQ2	Please check and confirm the order of organisation division and name processed in affiliations and amend if necessary.	
AQ3	Please check and provide indicator for superscript letter 'a' in table body.	
AQ4	Figures 3–5 are poor in quality as its labels are not readable. Please supply a new version of the said figure with legible labels preferably in .eps, .tiff or .jpeg format with 600 dpi resolution.	
AQ5	As conflict of interest statement is mandatory for this journal, please check and provide the same.	
AQ6	Please update Ref. Abbouda et al. (2014) with volume and page range if possible.	
AQ7	References Islas-Rodriguez et al. (2009) and Manning and Woody (1991) were provided in the reference list; however, this was not mentioned or cited in the manuscript. Please provide the location of where to insert the reference citation in the main body text.	